首页> 外文期刊>Journal of Drug Delivery and Therapeutics >Rationality of Fixed Dose Combinations of Central Nervous System Drugs in a Tertiary Care Hospital
【24h】

Rationality of Fixed Dose Combinations of Central Nervous System Drugs in a Tertiary Care Hospital

机译:三级医院中枢神经系统药物固定剂量组合的合理性

获取原文
           

摘要

Objectives: To analyze the rationality of central nervous system fixed dose combinations used in a tertiary care hospital. Methodology: The study was an hospital based observational study. The data was collected from an annual drug compendium entitled “Hospital Drug List”. Fixed dose combinations (FDCs) enlisted in central nervous system (CNS) sections were selected for the study purpose. The active pharmacological ingredients (APIs) in FDC was checked for approval by Drug Control General of India (DCGI), World Health Organization (WHO) and essential medicine (EML)ational essential medicine list (NEML),both or none and all the ingredients (molecule, excipients) present in the FDC was checked whether banned or under any controversies in India as well as worldwide. Efficacy and safety of the individual active pharmacological ingredients (APIs) and their combination were searched. Details of each drug were collected [Generic name, Pharmacokinetics, Interaction affected, Pharmacodynamics, and Advantages of FDCs]. The data collected was analyzed by a tool to assess the rationality of fixed dose combinations which is pre-tested and validated by Shah et al., based on WHO guidelines. Result and Discussion: A total of 25 CNS FDCs were taken, on assessment of CNS FDCs 21 (84%) were found to be rational and 4 (16%) were found to be irrational with the mean rationality score of 7.2. By winding up, state of nonbeing, absenteeism of legality and effectiveness of the formulations appeared in to a peculiar combinations and inadequate practice. The approval process of these combinations by various committees should be robust.
机译:目的:分析三级医院中枢神经系统固定剂量组合的合理性。方法:该研究是基于医院的观察性研究。该数据是从年度药物汇编中收集的,标题为“医院药物清单”。选择用于中枢神经系统(CNS)的固定剂量组合(FDC)。 FDC中的有效药理成分(API)已通过印度药物管制总局(DCGI),世界卫生组织(WHO)和基本药物(EML)/国家基本药物清单(NEML)的批准或全部检查,是否全部批准。检查FDC中存在的各种成分(分子,赋形剂)在印度乃至全世界是否被禁止或存在任何争议。搜索了各个活性药理成分(API)及其组合的功效和安全性。收集每种药物的详细信息[通用名称,药代动力学,受影响的相互作用,药效学和FDC的优点]。 Shah等人根据WHO准则,使用一种工具评估收集的数据,以评估固定剂量组合的合理性,该工具已由Shah等人进行了预先测试和验证。结果与讨论:共抽取25个中枢神经系统FDC,对中枢神经系统FDC的评估为21个(84%)是合理的,4个(16%)被认为是不合理的,平均合理性得分为7.2。通过清盘,异常状态,制剂合法性和有效性的缺席出现在特殊的组合和不充分的实践中。各个委员会对这些合并的批准过程应健全。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号